Literature DB >> 8593940

Treatment of diabetes by xenogeneic islets without immunosuppression. Use of a vascularized bioartificial pancreas.

T Maki1, I Otsu, J J O'Neil, K Dunleavy, C J Mullon, B A Solomon, A P Monaco.   

Abstract

Tight glycemic control by intensive insulin therapy effectively delays the onset and slows the progression of diabetic complications but is associated with frequent dose adjustments and a high incidence of hypoglycemia. Successful pancreas transplantation corrects abnormal glucose metabolism but subjects patients to morbidity and mortality associated with chronic immunosuppression. A vascularized artificial pancreas device containing pancreatic islets is designed to provide glycemic control without immunosuppression. We report here that devices seeded with porcine islets implanted into pancreatectomized severely diabetic dogs maintained a marked improvement in glycemic control with reduced exogenous insulin requirements for up to 9 months with improved glucose tolerance and a reduction in glycosylated hemoglobin levels. No immunosuppression was used. Thus, use of a vascularized artificial pancreas containing xenogeneic porcine islets could be an alternative to intensive insulin therapy and pancreatic transplantation in treating diabetic patients before the development of severe diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8593940     DOI: 10.2337/diab.45.3.342

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain.

Authors:  Esther S O'Sullivan; Arturo Vegas; Daniel G Anderson; Gordon C Weir
Journal:  Endocr Rev       Date:  2011-09-27       Impact factor: 19.871

2.  A rapid qualitative method to assess in vitro immunobarrier competence of pancreatic islets containing alginate/polyaminoacidic microcapsules.

Authors:  R Calafiore; G Basta; P Sarchielli; G Luca; C Tortoioli; P Brunetti
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

3.  An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport.

Authors:  Shang Song; Charles Blaha; Willieford Moses; Jaehyun Park; Nathan Wright; Joey Groszek; William Fissell; Shant Vartanian; Andrew M Posselt; Shuvo Roy
Journal:  Lab Chip       Date:  2017-05-16       Impact factor: 6.799

Review 4.  Engineering the vasculature for islet transplantation.

Authors:  Daniel T Bowers; Wei Song; Long-Hai Wang; Minglin Ma
Journal:  Acta Biomater       Date:  2019-05-23       Impact factor: 8.947

Review 5.  Encapsulated cell grafts to treat cellular deficiencies and dysfunction.

Authors:  N V Krishnamurthy; Barjor Gimi
Journal:  Crit Rev Biomed Eng       Date:  2011

Review 6.  Transplantation of Macroencapsulated Insulin-Producing Cells.

Authors:  Albert J Hwa; Gordon C Weir
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

Review 7.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

8.  Alginate encapsulation of human embryonic stem cells to enhance directed differentiation to pancreatic islet-like cells.

Authors:  Thomas Richardson; Prashant N Kumta; Ipsita Banerjee
Journal:  Tissue Eng Part A       Date:  2014-12       Impact factor: 3.845

Review 9.  Animal models of diabetes mellitus for islet transplantation.

Authors:  Naoaki Sakata; Gumpei Yoshimatsu; Haruyuki Tsuchiya; Shinichi Egawa; Michiaki Unno
Journal:  Exp Diabetes Res       Date:  2012-12-30

Review 10.  Transplantation of Encapsulated Pancreatic Islets as a Treatment for Patients with Type 1 Diabetes Mellitus.

Authors:  Meirigeng Qi
Journal:  Adv Med       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.